Related Experiment Video
Updated: Jul 4, 2025
Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
Safety and efficacy of epicutaneous immunotherapy with DBV712 (peanut patch) in peanut allergy
Christophe Dupont1, A Wesley Burks2, David M Fleischer3
1Pediatric Gastroenterology Department, Marcel Sembat Clinic, Ramsay Group, Boulogne Billancourt, France.
Introduction:
DBV712 250 µg (also referred to as Viaskin Peanut or peanut patch; Viaskin is a trademark of DBV Technologies) is an innovative approach to epicutaneous immunotherapy (EPIT). The patch-based technology system facilitates peanut protein (allergen) absorption into the intact non-vascularized epidermis to promote desensitization to peanut while limiting systemic allergen exposure.
Areas Covered:
Efficacy and safety in children have been evaluated in four completed phase 3 studies. Overall, the results from these studies have demonstrated the peanut patch to be superior in desensitization compared with placebo and safe for daily use over multiple years.
Expert Opinion:
These findings, as well as supportive evidence from phase 2 studies, confirm the potential for an effective treatment of peanut allergy in children. The purpose of this review is to summarize the safety and efficacy of the peanut patch in the treatment of peanut allergy.
